Chinese Scientists Develop Gene Therapy CS-101 Curing Five Beta-Thalassaemia Patients
Base-editing drug using transformer Base Editor technology frees patients from blood transfusions
Hızlı Bakış
- Scientists at ShanghaiTech University have developed CS-101, a base-editing gene therapy that successfully cured five Chinese patients with beta-thalassaemia.
- The treatment restored haematopoietic function, raising total haemoglobin and fetal haemoglobin levels, freeing patients from lifelong blood transfusions.
- China has 30 million thalassaemia gene carriers while the global total reaches 350 million.
Yapay zekâ özeti
Neden Önemli?
Thalassaemia is the world's most common genetic blood disorder. Patients with severe forms require regular blood transfusions and face potential organ transplants and premature death. When two carriers of the gene marry, their children have a 25 per cent chance of developing the disease.
Thalassaemia is the world's most common genetic blood disorder. China currently has 30 million thalassaemia gene carriers, while the global total reaches 350 million. Patient with severe thalassaemia could confront a stark reality: regular blood transfusions, potential organ transplants, and even the risk of premature death. If two carriers of the gene marry, their children have a 25 per cent chance of developing the disease. The therapy used CS-101, a base-editing drug developed for thalassaemia patients by scientists at ShanghaiTech University using transformer Base Editor (tBE) technology. Five Chinese patients with beta-thalassaemia who received CS-101 treatment rapidly restored haematopoietic function – the ability to produce healthy new blood cells. Total haemoglobin and fetal haemoglobin (HbF) levels rose quickly and stayed high, freeing them from blood transfusions.
Açık Sorular
- What is the long-term safety profile of CS-101?
- How many more patients need to be treated before regulatory approval?
- What is the cost of the treatment?
- Will this therapy work for other types of thalassaemia?
